Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.33 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12320966 | 0.75 | GAA (0.38) | HSD17B10GAAMAPTHTR5A | |
| SCHEMBL16104519 | 0.74 | ALOX15 (0.38) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL28212019 | 0.74 | ALOX15 (0.38) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL20613159 | 0.74 | ALOX15 (0.38) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL15889357 | 0.74 | ALOX15 (0.34) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL13554354 | 0.74 | ALOX15 (0.34) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL22352112 | 0.74 | HSD17B10 (0.43) | ALOX15HSD17B10BRPF1GAANPSR1 | |
| SCHEMBL30688538 | 0.71 | ALOX15 (0.37) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL28390255 | 0.71 | HSD17B3 (0.40) | ALOX15HSD17B10BRPF1GAAMAPT | |
| SCHEMBL30366037 | 0.71 | HSD17B3 (0.40) | ALOX15HSD17B10BRPF1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125708-A1 | P38 MAPK/MK2 PATHWAY MODULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125707-A1 | P38 MAPK/MK2 PATHWAY REGULATOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023098699-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-06-08 | — | — | WO | disclosed |
| EP-4183774-A1 | SULFONYLUREA DERIVATIVE AND MEDICAL USES THEREOF | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-05-24 | — | — | EP | disclosed |
| EP-4180422-A1 | SULFONYLBENZAMIDE DERIVATIVE AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022166799-A1 | FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| EP-3458444-B1 | HISTONE DEACETYLASE 6 INHIBITORS AND USE THEREOF | UNIV TAIPEI MEDICAL (TW) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022111644-A1 | SALT AND CRYSTAL FORM OF NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022007924-A1 | OXA-AZABICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-3929181-A1 | 6-OXO-1,6-DIHYDROPYRIDAZINE PRODRUG DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| EP-2561867-A1 | CDK9 inhibitors in the treatment of midline carcinoma | Lead Discovery Center GmbH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-8106051-B2 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | SHIONOGI & CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429593-B2 | Utilities of amide compounds | SHIONOGI & CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | YAMAMORI TERUO | 2008-09-11 | — | — | US | disclosed |
| US-5968725-A | MATERIAL COMPRISING ON SUPPORT SILVER HALIDE PHOTOSENSITIVE LAYER CONTAINING ORGANIC SILVER SALT, REDUCING AGENT, ULTRAHIGH CONTRAST PROMOTING AGENT, SELECTED HETEROCYCLIC MERCAPTO COMPOUND | FUJI PHOTO FILM CO., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5236807-A | Negative, hydrazine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1993-08-17 | — | — | US | disclosed |
| US-4769316-A | Method for restraining the formation of re-reversal negative image in direct positive silver halide photographic materials | FUJI PHOTO FILM CO., LTD. (JP) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221112-A1 | 4-Chloro-N-(4-tolyl)benzamide; to enhance the serum level of apoAI | APOL1, PON1, APOB | ALOX15 836/4885HSD17B10 1169/4885BRPF1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.